PDE4A and polycystic ovary syndrome: Furthermore, clinical studies demonstrated that the PDE4 inhibitor roflumilast added to metformin reduced fat mass in obese women with PCOS69, suggesting that hyperandrogenemia may lead to decreased cAMP levels in WAT.